Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

April 30, 2028

Conditions
Pancreatic Cancer
Interventions
PROCEDURE

Biopsy

Pre-treatment tumor biopsy

DRUG

FOLFIRINOX

"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"

DRUG

Ciprofloxacin

Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.

DRUG

Metronidazole

Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.

DRUG

Pembrolizumab

Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.

PROCEDURE

Surgical Resection

Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER